Nutriband Inc. Warrant

NTRBW

Market cap $1.13M

1.50 USD

0.00

0%

At close Updated Aug 29, 10:56 AM EDT

1 day

0%

5 days

47.06%

1 month

-26.11%

3 months

4.9%

6 months

-51.61%

Year to date

-12.28%

1 year

57.89%

5 years

3.45%

10 years

3.45%

About: Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

Employees: 3

Healthcare Biotechnology

0

Funds holding %

of 7,445 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

33% more funds holding

Funds holding: 3 [Q1] → 4 (+1) [Q2]

25.3% more ownership

Funds ownership: 1.85% [Q1] → 27.14% (+25.3%) [Q2]

4% more capital invested

Capital invested by funds: $314K [Q1] → $326K (+$11.9K) [Q2]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

See Fund Rankings

Financial journalist opinion

Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election

Sheridan will temporarily step aside as CEO to enter the Irish Presidential Election. Company Chairman and President, Serguei Melnik will take over as interim CEO over the course of the campaign and election period.

Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election

FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

FDA grants meeting for AVERSA™ FENTANYL (abuse deterrent transdermal system) to provide feedback on the Chemistry, Manufacturing, and Controls plans for the product through commercialization. Nutriband is partnering with Kindeva to develop AVERSA™ FENTANYL which combines Nutriband's AVERSA™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch.

FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval

ORLANDO, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) (“Nutriband” or the “Company”) is today reminding shareholders of the key dates associated with its upcoming 25% Preferred stock dividend.

Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval

Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval

ORLANDO, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) (“Nutriband” or the “Company”) announced today that its Board of Directors has approved and declared a 25% preferred stock dividend.

Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval

Nutriband Inc. added to the Russell Microcap® Index, Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index

ORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), has been added as a member of the Russell Microcap, Russell Microcap Growth, Russell 3000E and Russell 3000E Growth Indexes, as part of the 2025 Russell indexes reconstitution.

Nutriband Inc. added to the Russell Microcap® Index, Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index

Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology

Patent issuance expands United States patent coverage for AVERSA™ transdermal abuse deterrent technology AVERSA™ transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. ORLANDO, Fla.

Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology

Nutriband CEO Publishes Letter to Shareholders

ORLANDO, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2024 and the potential outlook for 2025.

Nutriband CEO Publishes Letter to Shareholders

Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology

ORLANDO, Fla., April 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received notification that its patent has been granted in Macao for its patent entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA™ abuse deterrent transdermal technology.

Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology

UPDATE – Nutriband Signs Associate Partnership with Charlotte FC

ORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has signed an Associate Partnership agreement with Charlotte FC.

UPDATE – Nutriband Signs Associate Partnership with Charlotte FC

Nutriband Signs Partnership Agreement with Charlotte FC

ORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has signed an Associate Partnership agreement with Charlotte FC.

Nutriband Signs Partnership Agreement with Charlotte FC

See News Rankings

Charts implemented using Lightweight Charts™